Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


P&G/Wella deal

This article was originally published in The Rose Sheet

Executive Summary

Procter & Gamble will make a cash only tender offer of $65.70 (€1=$1.07) per share for Wella preference shares as part of acquisition agreement. Cash only offer will speed up the tender process and regulatory clearance, P&G says. During consumer products manufacturer's March 18 announcement it would acquire Wella, company indicated it would consider offering P&G shares to Wella's preference shareholders as alternative to cash (1"The Rose Sheet" March 24, 2003, p. 3). P&G plans to submit tender offer documentation during the week of April 7, and assuming regulatory acceptance, offer is expected to commence in late April, firm adds...

You may also be interested in...

Wella Complementary Salon Portfolio “On Strategy” For P&G - Lafley

The addition of Wella's professional hair care portfolio to Procter & Gamble's retail hair care assortment will position the Cincinnati-based consumer products marketer as a leader in salons and enhance its strategic position versus market-leading rival L'Oréal

FDA Slacking In NDI Notification Enforcement; COVID-19 'Is Not An Excuse’ – NPA

In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.

Finance Watch: Four IPOs In One Week, And Legend Is Year’s Largest So Far

Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts